Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’

Overview of attention for article published in Diabetes Therapy, September 2015

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 50 Dimensions

Readers on

mendeley: 57 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 1,520 followers.

@drsamsilver @askrenal Unclear. Here’s data from all the dapa trials: Few numbers and wide confidence intervals but characteristics of the patients were the same as non dapa bladder cancer in the population. Lousy, inconclusive, I know. https://t.co/KXKfJ

17 Jun 2022

Reply Repost Favourite

Bladder cancer risk in #T2DM: the #dapagliflozin drug development program as a ‘case study’ http://t.co/Dp4h2gHBLL http://t.co/YoAf8ry4Iv

09 Sep 2015

Reply Repost Favourite

Bladder cancer risk in #T2DM: the #dapagliflozin drug development program as a ‘case study’ http://t.co/Dp4h2gHBLL

02 Sep 2015

Reply Repost Favourite